Home' Australian Pharmacist : June 2011 Contents Vol. 30 -- June #06
Continuing Professional Development
Submit your answers online at www.psa.org.au and receive automatic feedback
To answer Knowledge in
Answers for Knowledge in practice
can only be submitted online through
the PSA members-only area of the
PSA website at: www.psa.org.au
PSA members will receive instant
feedback on the correct answers with
an explanation of why the answer is
correct. If you do not have member
access details for the PSA website,
you can request them via a link from
the login page.
Note: The CPD questions are now at
the end of each article.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from the
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers before 1 August 2011
or fax/mail to:
(04) 381 4786
NZCP Mail address: NZCP CPD answers
PO Box 11 640
(03) 9389 4044
PSA Mail address: PSA CPD answers
PSA Victorian Branch
Level 1, 381 Royal Parade
PARKVILLE VIC 3052
online at www.psa.org.au and receive automatic feedback
Australian Pharmacist Continuing Professional Development (CPD) is a central
element of PSA's CPD&PI program. It is also part of the New Zealand College of
Pharmacists (NZCP) education program for NZ pharmacists.
The CPD section is recognised under the PSA CPD&PI program as a Group 2 activity.
Members can choose which articles they want to answer questions on and get CPD
credits based on the questions they answer. The credits allocated to each section
and the pass mark are shown with the questions.
CPD credits are allocated as follows: a minimum of 6 out of 8 questions correct
attracts 1.5 credits, a minimum of 4 out of 5 questions correct attracts 1 credit, and
a minimum of 3 out of 4 questions correct attracts three quarters of a credit.
If not submitting online, write the correct answers in the spaces provided on the
answer panel on the back of the address sheet, fill in your name, member number
and address details, then either mail or fax the answer page to the relevant address
and fax number for marking.
Of the following recommendations,
what is the most appropriate advice
to provide to Mrs Smith's GP:
a) Recommend ceasing methotrexate
and adding infliximab to Mrs
Smith's regimen instead.
b) Recommend ceasing rosiglitazone
and adding pioglitazone to Mrs
Smith's regimen instead.
c) Recommend ceasing naproxen
and adding diclofenac 50 mg three
times daily to Mrs Smith's regimen
d) Recommend ceasing risedronate
and adding zoledronic acid to
Mrs Smith's regimen instead.
Australian MS research
Australia is increasing its
contribution to multiple sclerosis
(MS) research, but existing
treatments remain the frontline
in tackling this incurable disease,
according to MS experts who
gathered in Sydney last month to
discuss latest developments in MS.
Speaking in Sydney ahead of MS
Awareness Day on 25 May and
MS Awareness Week (30 May to 5
June), Professor Graeme Stewart
of the Westmead Millennium
Institute and Dr Michael Barnett,
Senior Lecturer at the University
of Sydney, explained that while no
cure currently exists for multiple
sclerosis, doctors and scientists
are making discoveries every day
in treating and understanding the
Professor Stewart said, 'Australian
researchers, supported by Multiple
Sclerosis Research Australia
(MSRA), have made a major
contribution to the discovery in
2011 of many of the genetic factors
that contribute to the cause of
MS -- the "MS genes"
. Each of
these provides a new lead towards
unlocking the mystery of MS and
finding a cure. There has never been
a better time to be in MS research.
Dr Barnett said, 'The advent of
effective oral therapies for multiple
sclerosis is an exciting development
for both patients and neurologists.
However, our enthusiasm should be
tempered by a lack of long term data,
particularly with regard to medication
safety. Treatments that have been
in the market place for a number of
years with proven long term efficacy
and safety remain at the therapeutic
frontline of this incurable disease.
This year, MS Awareness Day
hopes to raise awareness of
employment issues and encourage
workplaces to be more flexible,
understanding and encouraging.
Around 80% of people with
MS will lose their job within 10
years of diagnosis, often in their
30s or 40s, without adequate
retirement savings and with risks of
Links Archive July 2011 May 2011 Navigation Previous Page Next Page